Utility and safety of coronary angiography in patients with acute infective endocarditis who required surgery.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
09 2022
Historique:
received: 10 03 2020
revised: 09 08 2020
accepted: 15 08 2020
pubmed: 3 11 2020
medline: 18 8 2022
entrez: 2 11 2020
Statut: ppublish

Résumé

To assess the benefit/risk ratio to perform a coronary angiography (CA) before surgery for infective endocarditis (IE). We conducted a single-center prospective registry including 272 patients with acute IE intended for surgery and compared patients who underwent a preoperative CA (n = 160) with those who did not (n = 112). A meta-analysis of 3 observational studies was also conducted and included 551 patients: 342 who underwent a CA and 209 who did not. In our registry, combined bypass surgery (CABG) was performed in 17% of the patients with preoperative CA. At 2 years, the rate of the primary composite end point (all-cause death, new systemic embolism, stroke, new hemodialysis) was similar in the CA (38%) and no-CA (37%) groups. In-hospital and 2-year individual end points were all similar between groups. There were only 2 episodes of systemic embolism after CA and only one possibly related to a vegetation dislodgement. In the meta-analysis, combined CABG was performed in 18% of the patients with preoperative CA. All-cause death was similar in both groups: odds ratio, 0.98 [0.62-1.53], P = .92. Only 5 cases of systemic embolism possibly related to a vegetation dislodgement were reported. New hemodialysis was numerically more frequent in the CA group: odds ratio, 1.68 [0.79-3.58] (18% vs 14%, P = .18). In daily practice, two-thirds of the patients with acute IE who required surgery have a preoperative CA leading to a combined CABG in 18% of the patients. Our results suggest that to perform a preoperative CA in this context is not associated with improved prognosis.

Identifiants

pubmed: 33131891
pii: S0022-5223(20)32700-8
doi: 10.1016/j.jtcvs.2020.08.117
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

905-913.e19

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Théo-Alexandre Spanneut (TA)

USIC et Centre Hémodynamique, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France.

Pierre Paquet (P)

USIC et Centre Hémodynamique, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France.

Christophe Bauters (C)

Service de Cardiologie, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France; INSERM UMR 1067, Institut Pasteur de Lille, Lille, France; Faculté de Médecine de l'Université de Lille, Lille, France.

Thomas Modine (T)

Service de chirurgie cardiaque et vasculaire, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France.

Marjorie Richardson (M)

Service d'exploration fonctionnelle cardiovasculaire, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France.

Laurent Bonello (L)

Service de Cardiologie, Hopital Nord de Marseille, Assistance Publique des Hôpitaux de Marseille, Marseille, France.

Francis Juthier (F)

Faculté de Médecine de l'Université de Lille, Lille, France; Service de chirurgie cardiaque et vasculaire, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France; INSERM UMR 1011, Institut Pasteur de Lille, Lille, France.

Gilles Lemesle (G)

USIC et Centre Hémodynamique, Institut Coeur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France; Faculté de Médecine de l'Université de Lille, Lille, France; INSERM UMR 1011, Institut Pasteur de Lille, Lille, France; FACT (French Alliance for Cardiovascular Trials), Paris, France. Electronic address: gilles_lemesle@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH